Longbio Pharma

Focus: Longbio Pharma is a China-based biopharmaceutical company focused on monoclonal antibodies targeting allergy and complement-mediated diseases. The company operates as a clinical-stage player with a diversified pipeline spanning multiple therapeutic areas.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Longbio Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Longbio Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LP-005 Dose 1

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

Clinical Trials (1)

NCT06294301A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Phase 1

Help build intelligence for Longbio Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-demand therapeutic areas (allergy, complement disease) with 13 active trials and advancement to Phase 3 in seasonal allergic rhinitis
mAb-based platform offers deep technical expertise opportunity in antibody engineering and development
China-based headquarters provides access to growing Asian biotech ecosystem and regulatory pathways

Watch Out For

Zero current open positions and no hiring activity signals contraction or hiring freeze
No disclosed funding, revenue, or financial data raises questions about capitalization and runway sustainability
Early-stage pipeline (5 Phase 1, 8 Phase 2 programs) with minimal near-term revenue catalysts and significant development risk

Generated by Claude from Longbio Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LP-003 200mg

Chronic Spontaneous Urticaria

Phase 1

Clinical Trials (1)

NCT06604949A Study of Single Dose of LP-003 in Healthy Adult Subjects

Phase 1

LP-001 Dose 1

Myelodysplastic Syndrome (MDS)

Phase 1

Clinical Trials (1)

NCT06294275A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Phase 1